Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24707902 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL30342352 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10137666 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10137713 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL25608131 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL6065186 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL1052921 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL1051376 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10585442 | 0.88 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10054586 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206748-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2025-06-26 | — | — | US | disclosed |
| CN-115746003-B | Methods of making and using PDE9 inhibitors | 卡都瑞恩医药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4335497-A2 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2024-03-13 | — | — | EP | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| CN-116997546-A | APOL1 inhibitors and methods of use | 梅兹治疗公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-3630772-B1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | IMARA INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2938608-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | GLS2, PYGL, CPS1 | NR1H2 2312/4885USP2 3974/4885SMN1; SMN2 2157/4885 |
| US-20250206748-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | NR1H2 4354/4885USP2 2094/4885SMN1; SMN2 1150/4885 |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | NR1H2 750/4885USP2 3615/4885SMN1; SMN2 939/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | NR1H2 2191/4885USP2 14/4885SMN1; SMN2 3600/4885 |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | DNPEP, PRKCSH, YWHAZ | NR1H2 3455/4885USP2 402/4885SMN1; SMN2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.